trending Market Intelligence /marketintelligence/en/news-insights/trending/toB8YECTuq_K9NgN7UCAEg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Ascendis wins EU orphan designation for growth hormone deficiency therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Ascendis wins EU orphan designation for growth hormone deficiency therapy

Ascendis Pharma A/S's growth hormone therapy for pediatric patients with growth hormone deficiency was granted orphan designation by the European Commission.

The Danish biopharmaceutical company's TransCon Growth Hormone is in development as a once-weekly treatment for pediatric growth hormone deficiency. It provides sustained release of the growth hormone at a calculated rate over one week.

On March 4, the company disclosed results from a late-stage study showing that TransCon Growth Hormone therapy encouraged more growth in pediatric patients with growth hormone deficiency than Pfizer Inc.'s daily Genotropin medicine.

Ascendis said in an Oct. 21 news release that it plans to file for a U.S. Biologics License Application in the first half of 2020 and a marketing application in Europe in the second half of 2020 for TransCon Growth Hormone.

There are no approved long-acting growth hormone treatments in Europe currently.

The European Commission's orphan designation is granted to therapies aimed at the treatment, prevention or diagnosis of a life-threatening disease that affects no more than five in 10,000 people in the EU and for which satisfactory treatment is unavailable. Drugs with the orphan tag have 10 years of market exclusivity after they receive market authorization in the EU and the tag supports future reimbursement and access to new therapies.